11 March 2022
Backing the Microbiome: The Investor Perspective
Life science research changes frequently, with new discoveries being published every day. Some of these discoveries form the basis of new biotech companies, but whether or not...
Life Sciences
7 March 2022
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series...
22 February 2022
Polaris and Golden Omega partner for the North American market
Polaris and Golden Omega are pleased to announce a new alliance which will allow Polaris to use Golden Omega’s extensive network in the North American Market for the...
20 February 2022
OIA launches project to produce alternative protein from dates
Focusing on its role in attracting foreign investments and advanced technologies to the sultanate, Oman Investment Authority (OIA) has signed an agreement with US-based...
14 February 2022
Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival...
19 January 2022
The start-up La Vie™ raises €25M and sets out to conquer the world with its new generation of plant-based meat
The first record raising of €25M in Series A financing from investment funds led by Seventure, and international celebrities that are committed to protecting the planet. This...
13 January 2022
Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge
DERMALA, a consumer dermatology company that develops novel treatments for chronic skin conditions, announces the brand's Grand Prize recognition in the global pitch...
3 November 2021
MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
MaaT Pharma S.A. ("MaaT Pharma" or the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome2-based ecosystem therapies dedicated to...
27 October 2021
Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, today announced that the...
14 October 2021
Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million
Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept.